Literature DB >> 16496045

Molecular heterogeneity analysis of poly(amidoamine) dendrimer-based mono- and multifunctional nanodevices by capillary electrophoresis.

Xiangyang Shi1, István J Majoros, Anil K Patri, Xiangdong Bi, Mohammad T Islam, Ankur Desai, T Rose Ganser, James R Baker.   

Abstract

Poly(amidoamine) (PAMAM) dendrimer-based nanodevices are of recent interest in targeted cancer therapy. Characterization of mono- and multifunctional PAMAM-based nanodevices remains a great challenge because of their molecular complexity. In this work, various mono- and multifunctional nanodevices based on PAMAM G5 (generation 5) dendrimer were characterized by UV-Vis spectrometry, (1)H NMR, size exclusion chromatography (SEC), and capillary electrophoresis (CE). CE was extensively utilized to measure the molecular heterogeneity of these PAMAM-based nanodevices. G5-FA (FA denotes folic acid) conjugates (synthesized from amine-terminated G5.NH(2) dendrimer, approach 1) with acetamide and amine termini exhibit bimodal or multi-modal distributions. In contrast, G5-FA and bifunctional G5-FA-MTX (MTX denotes methotrexate) conjugates with hydroxyl termini display a single modal distribution. Multifunctional G5.Ac(n)-FI-FA, G5.Ac(n)-FA-OH-MTX, and G5.Ac(n)-FI-FA-OH-MTX (Ac denotes acetamide; FI denotes fluorescein) nanodevices (synthesized from partially acetylated G5 dendrimer, approach 2) exhibit a monodisperse distribution. It indicates that the molecular distribution of PAMAM conjugates largely depends on the homogeneity of starting materials, the synthetic approaches, and the final functionalization steps. Hydroxylation functionalization of dendrimers masks the dispersity of the final PAMAM nanodevices in both synthetic approaches. The applied CE analysis of mono- and multifunctional PAMAM-based nanodevices provides a powerful tool to evaluate the molecular heterogeneity of complex dendrimer conjugate nanodevices for targeted cancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16496045     DOI: 10.1039/b515624f

Source DB:  PubMed          Journal:  Analyst        ISSN: 0003-2654            Impact factor:   4.616


  7 in total

1.  Antibacterial activity and cytotoxicity of PEGylated poly(amidoamine) dendrimers.

Authors:  Analette I Lopez; Rose Y Reins; Alison M McDermott; Barbara W Trautner; Chengzhi Cai
Journal:  Mol Biosyst       Date:  2009-07-03

2.  Convergent assembly and surface modification of multifunctional dendrimers by three consecutive click reactions.

Authors:  Petr A Ledin; Frédéric Friscourt; Jun Guo; Geert-Jan Boons
Journal:  Chemistry       Date:  2010-11-17       Impact factor: 5.236

3.  Targeting the efficacy of a dendrimer-based nanotherapeutic in heterogeneous xenograft tumors in vivo.

Authors:  Andrzej Myc; Jolanta Kukowska-Latallo; Peter Cao; Ben Swanson; Julianna Battista; Thomas Dunham; James R Baker
Journal:  Anticancer Drugs       Date:  2010-02       Impact factor: 2.248

4.  Systematic investigation of polyamidoamine dendrimers surface-modified with poly(ethylene glycol) for drug delivery applications: synthesis, characterization, and evaluation of cytotoxicity.

Authors:  Yoonkyung Kim; Athena M Klutz; Kenneth A Jacobson
Journal:  Bioconjug Chem       Date:  2008-07-09       Impact factor: 4.774

5.  Click synthesis of a polyamidoamine dendrimer-based camptothecin prodrug.

Authors:  Olga Yu Zolotarskaya; Leyuan Xu; Kristoffer Valerie; Hu Yang
Journal:  RSC Adv       Date:  2015-06-29       Impact factor: 3.361

6.  The role of ganglioside GM1 in cellular internalization mechanisms of poly(amidoamine) dendrimers.

Authors:  Seungpyo Hong; Rahul Rattan; István J Majoros; Douglas G Mullen; Jennifer L Peters; Xiangyang Shi; Anna U Bielinska; Luz Blanco; Bradford G Orr; James R Baker; Mark M Banaszak Holl
Journal:  Bioconjug Chem       Date:  2009-07-07       Impact factor: 4.774

Review 7.  Targeted nanosystems: Advances in targeted dendrimers for cancer therapy.

Authors:  Hu Yang
Journal:  Nanomedicine       Date:  2015-12-17       Impact factor: 5.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.